Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study
- Registration Number
- NCT02342392
- Lead Sponsor
- Universiti Sains Malaysia
- Brief Summary
The purpose of this study is to evaluate the pterygium vascularity and size before and after intralesional ranibizumab injection and to evaluate its recurrence rate following pterygium excision surgery.
- Detailed Description
The purpose of this study is to:
1. Compare the vascularity of primary pterygium before and 1 week after intralesional ranibizumab (0.3 mg/0.03 mL) injection.
2. Compare the size of primary pterygium before and 1 week after intralesional ranibizumab (0.3 mg/0.03 mL) injection.
3. Compare the recurrence rate at 1 year after pterygium excision surgery between the group with and without intralesional ranibizumab injection.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 36
- All patients with primary pterygium.
- Grade T3 (fleshy) pterygium.
- Patients with other ocular surface disorders.
- Previous ocular surgery or trauma.
- History of systemic thromboembolic event.
- Pregnant women and lactating mother.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description treatment group ranibizumab intralesional ranibizumab injected
- Primary Outcome Measures
Name Time Method pterygium recurrence 1 year pterygium recurrence is defined as true recurrence with a fibrovascular tissue invading the cornea (grade 4 lesion)
- Secondary Outcome Measures
Name Time Method pterygium vessel area 1 week Pterygium vesel area is defined as the as the ration of pixels occupied by the vessels within the pterygium area in percentage.
corneal pterygium area 1 week Corneal pterygium area is defined as the as the ration of pixels occupied by the pterygium within the cornea area in percentage.